Dexpanthenol
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Dexpanthenol: From Wound Healing and Skin Repair to Anorectal Stricture
One-Sentence Summary
Dexpanthenol (provitamin B5) is a well-established skin and mucosal healing agent, marketed as Bepanthen® in numerous countries, used for wound care, skin barrier repair, and post-procedure recovery — though it holds no regulatory approval in Taiwan. The TxGNN model ranks Anorectal Stricture as its top predicted new indication, with a prediction score of 99.72%. However, no clinical trials or published literature currently support this specific application, and the mechanistic rationale faces a fundamental challenge: anorectal stricture is a structural/fibrotic condition that cannot be reversed through pharmacological means alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Wound healing, skin barrier repair, mucosal recovery (general use; no regulatory record in Taiwan) |
| Predicted New Indication | Anorectal Stricture |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (0 approved products) |
| Number of Approved Licenses | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Dexpanthenol is the alcohol form of pantothenic acid (vitamin B5). Once absorbed, it is enzymatically converted to pantothenic acid and incorporated into Coenzyme A (CoA) — a central cofactor in fatty acid synthesis, energy metabolism, and cellular repair. Through this pathway, dexpanthenol supports lipid synthesis in the skin barrier, stimulates keratinocyte and epithelial cell proliferation, suppresses pro-inflammatory cytokines such as IL-1α, and accelerates wound and mucosal healing. The Bepanthen® Rectal formulation (containing approximately 2.75% dexpanthenol) is available in several European markets for anorectal discomfort, providing indirect evidence that the drug is tolerated in this anatomical region.
Anorectal stricture, however, is a narrowing of the anal canal caused predominantly by fibrous scarring — typically following anorectal surgery, radiation therapy, or chronic inflammatory disease. Fibrosis involves irreversible collagen deposition and tissue remodeling that dexpanthenol’s mucosal-repair mechanism cannot reverse. Standard management is mechanical (graduated dilation) or surgical (anoplasty, flap repair). There is no established pharmacological pathway by which CoA-mediated epithelial healing would address the underlying fibrous architecture.
The TxGNN model likely assigned a high score due to anatomical proximity within the knowledge graph — shared ontological nodes between anorectal conditions where dexpanthenol has recognized activity (mucosal soothing, post-hemorrhoidectomy care) and anorectal stricture. This is a known limitation of graph-based prediction models: anatomical co-location can inflate scores in the absence of mechanistic specificity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Anorectal stricture is fundamentally a structural/fibrotic condition requiring mechanical dilation or surgical reconstruction. Dexpanthenol’s established mechanism — epithelial repair via CoA-mediated lipid and energy metabolism — has no established pathway to reverse anal canal fibrosis, and the absence of any supporting preclinical, clinical, or literature evidence at this time does not justify advancement.
To proceed, the following is needed:
- Preclinical evidence (animal models of anal canal fibrosis or radiation-induced stricture) demonstrating that dexpanthenol reduces collagen deposition or stricture severity
- Mechanistic data showing anti-fibrotic activity beyond epithelial healing — e.g., CoA pathway influence on TGF-β signaling or myofibroblast activation
- If clinical interest remains, consider reframing the research question as post-operative mucosal healing to prevent stricture formation (rather than reversing established stricture), which is more aligned with the drug’s known biology
- MOA data from DrugBank to formally characterize anti-fibrotic potential
- Safety profile data (package insert warnings, contraindications) before any clinical research can be initiated
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.